The present disclosure relates to a method for preparing a compound of formula (1). ##STR00001## In the compound of formula (1), n may be 0 to 5 and each of R.sub.1, R.sub.2, R.sub.3, and R.sub.4 may be independently selected from the group consisting of H, —O-Alkyl, halo, alkyl, —CN, or —NO.sub.3.

The present disclosure relates to a method for preparing a compound of formula (1). ##STR00001## In the compound of formula (1), n may be 0 to 5 and each of R.sub.1, R.sub.2, R.sub.3, and R.sub.4 may be independently selected from the group consisting of H, —O-Alkyl, halo, alkyl, —CN, or —NO.sub.3.

Described herein are methods of treating neuron inflammation conditions, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutically effective amount of cromolyn or a cromolyn derivative compound.

Described herein are methods of treating neuron inflammation conditions, for example, Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, and prion disease, comprising administering a therapeutically effective amount of cromolyn or a cromolyn derivative compound.

The present invention provides compounds that modulate the interaction of TCR with Nck, compositions thereof, and methods of treatment using the same.

The present invention provides compounds that modulate the interaction of TCR with Nck, compositions thereof, and methods of treatment using the same.

The present disclosure relates to compounds of Formula (I):

##STR00001##

and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for the treatment of disorders in which expression of P-glycoprotein and/or cytochrome P450 (e.g., CYP3A4) is modulated (e.g., cancers which have developed multi-drug resistance).

The present disclosure relates to compounds of Formula (I):

##STR00001##

and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for the treatment of disorders in which expression of P-glycoprotein and/or cytochrome P450 (e.g., CYP3A4) is modulated (e.g., cancers which have developed multi-drug resistance).

Palladium catalysts, methods of synthesizing palladium-carbene catalysts, and methods of producing chromones and aurones using palladium-N-heterocyclic carbene (NHC) catalysts are provided. In some implementations, the palladium catalysts include a bridged palladium catalyst with distorted square planar geometry around the center palladium atom. The catalysts can be used in cyclocarbonylative Sonogashira cross-coupling reactions to produce chromones and aurones at a high yield. The selectivity of the catalysts can be adjusted by adjusting reaction conditions.

Compounds that inhibit HIF-2α, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2α.